NCT05208944 2026-04-14
THIO Sequenced With Cemiplimab in Advanced NSCLC
Maia Biotechnology
Phase 2 Recruiting
Clinical Trials
28 trialsNCT05968326 2026-04-13
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
NCT07259317 2026-03-27
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Corcept Therapeutics
Phase 2 Recruiting
NCT02133196 2026-03-24
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07332000 2026-03-20
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Candel Therapeutics, Inc.
Phase 2 Recruiting
NCT06205836 2026-03-17
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06957691 2026-03-09
Fezo-ADT
Brigham and Women's Hospital
Phase 2 Recruiting
NCT05672524 2026-03-04
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT06616597 2026-02-19
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05620628 2026-01-21
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)
Samsung Medical Center
Phase 2 Recruiting
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT06844383 2025-10-29
TALENT
Prostate Cancer Clinical Trials Consortium
Phase 2 Recruiting
NCT07179783 2025-09-18
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT07018570 2025-08-26
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Recruiting
NCT06038578 2025-08-03
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Toray Industries, Inc
Phase 2 Recruiting
NCT04069273 2025-07-31
SEQUEL
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06687876 2025-07-10
MEMENTO
Amsterdam UMC, location VUmc
Phase 2 Recruiting
NCT07038304 2025-06-26
OLYMPIAN
University Medical Center Groningen
Phase 2 Recruiting
NCT04543071 2025-06-19
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Columbia University
Phase 2 Recruiting
NCT07026149 2025-06-18
Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Ruijin Hospital
Phase 2 Recruiting
NCT05241249 2025-06-05
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Columbia University
Phase 2 Recruiting
NCT05776524 2025-03-25
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
THERABIONIC INC.
Phase 2 Recruiting
NCT05476796 2024-10-24
LOGICAN
UNICANCER
Phase 2 Recruiting
NCT06636682 2024-10-21
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Cellvax Therapeutics Inc
Phase 2 Recruiting
NCT06121700 2023-11-08
Miracle-G
Fudan University
Phase 2 Recruiting
NCT04974866 2023-03-29
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma
Qingdao Central Hospital
Phase 2 Recruiting
NCT04018872 2021-11-04
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Dallas VA Medical Center
Phase 2 Recruiting